CCIA
VIR icon

Campbell & Co Investment Adviser’s Vir Biotechnology VIR Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,369
Closed -$92.9K – 1375
2026
Q1 		$92.9K Sell
10,369
-49,415
-83% -$394K 0.01% 1003
2025
Q4 		$360K Buy
+59,784
New +$356K 0.02% 930

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Campbell & Co Investment Adviser's VIR Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 10,369 shares — an estimated $92.9K sold.

Campbell & Co Investment Adviser first reported a position in VIR in Q4 2025 and held it in 2 quarters. The position peaked at $360K in Q4 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 10,369 Vir Biotechnology shares in Q2 2026, an estimated $92.9K.
  • Campbell & Co Investment Adviser first reported a position in Vir Biotechnology in Q4 2025 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Vir Biotechnology position peaked at $360K in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.